Business context and reporting period
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing LSTA1 for solid tumors and autologous CD34+ cell therapies for ischemic diseases. This Form 10-K reports the fiscal year ended December 31, 2022, with 2021 comparatives; although the request metadata says “2021 Q4,” that does not match the filing period. The filing was signed March 30, 2023.
On September 15, 2022, the company completed its acquisition of Cend Therapeutics, changed its name from Caladrius Biosciences, and effected a 1-for-15 reverse stock split. The merger was accounted for as an asset acquisition, with Caladrius identified as the accounting acquirer.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $13.1 million | $17.6 million |
| In-process research and development expense | $30.4 million | None |
| General and administrative expense | $14.1 million | $11.5 million |
| Total operating expenses | $57.6 million | $29.1 million |
| Net loss | $54.2 million | $27.5 million |
| Basic and diluted loss per share | $10.47 | $7.45 |
| Net cash used in operating activities | $21.2 million | $22.2 million |
At December 31, 2022, cash and cash equivalents were $32.2 million and marketable securities were $37.1 million, totaling $69.2 million. Working capital was $65.5 million; total assets were $73.0 million, total liabilities $6.7 million, and stockholders’ equity $66.6 million. The filing reports no debt balance; operating lease liabilities totaled $0.5 million. No revenue was recognized in either year, so revenue margins are not meaningful.
Management said available cash and marketable securities were expected to fund operating expenses for at least 12 months following issuance of the financial statements. The company reported no off-balance-sheet arrangements.
Material changes versus the prior year
- Net loss increased by $26.8 million. The principal driver was the $30.4 million non-routine IPR&D charge from the Cend acquisition; excluding that charge, operating expenses declined by $1.8 million, or 6.3%.
- R&D expense fell 25.7%, mainly reflecting suspension and close-out of the XOWNA FREEDOM trial and HONEDRA study activities, partly offset by LSTA1 manufacturing and clinical work.
- G&A expense rose 23.2%, reflecting merger and strategic-transaction costs, equity compensation, and other corporate costs.
- Operating cash use was $21.2 million, modestly lower than $22.2 million in 2021. Cash and marketable securities combined declined from $95.0 million to $69.2 million.
- The merger consideration was valued at $36.1 million, including $30.4 million of IPR&D expensed immediately. Lisata issued 3.77 million shares to Cend holders and assumed Cend options.
Outlook, management commentary, and key risks
- LSTA1: The lead program is in clinical development across solid tumors, including metastatic pancreatic cancer. In a completed 31-patient Phase 1b study, the company reported a 59% objective response rate and median overall survival exceeding 13 months. These results are from an early-stage study and do not establish comparative efficacy. The filing describes ongoing and planned studies, but gives no revenue or profitability guidance.
- XOWNA: Enrollment in the Phase 2b FREEDOM trial was suspended in 2022. Management determined a redesigned trial would require a strategic partner to fund it; development will continue only if such a partner is secured.
- HONEDRA: Enrollment in the Japan study was suspended amid COVID-19 disruption. The company reported completing protocol-defined follow-up and entering PMDA pre-consultation, while seeking a Japanese development partner. Formal consultation was anticipated during 2023, subject to the regulatory process.
- LSTA201: The six-patient diabetic kidney disease study was completed in 2022. Top-line results reported in February 2023 indicated acceptable safety but no consistent increase in glomerular filtration rate. Further development would require substantial capital and is contingent on a strategic partner.
- Funding and dilution: Lisata expects continuing losses and negative operating cash flow and may need additional financing, collaborations, or asset transactions. Equity financing could dilute shareholders; debt could impose repayment obligations and restrictive covenants. The company had an ATM facility, but reported no shares issued under it through year-end 2022.
- Other risks and contingencies: Key risks include clinical and regulatory failure, patient-enrollment and manufacturing constraints, dependence on third parties, limited commercial capabilities, intellectual-property and integration risks, and possible Nasdaq listing noncompliance. Lingmed Limited has sued over an alleged success fee connected to Cend’s Qilu agreement; Lisata denies the allegations and says it will defend the claim. Management did not believe pending claims would materially affect financial condition or operating results.
- Tax and unusual items: The company received $2.3 million net proceeds from selling New Jersey NOL tax benefits, recorded as a $2.5 million income-tax benefit with a related $0.1 million loss on sale. Federal NOL utilization is significantly limited by ownership changes; management recorded a full valuation allowance against net deferred tax assets.
Important facts for investors to verify
- Confirm the actual reporting period: this is a 2022 Form 10-K, not a 2021 year-end filing.
- Review current cash burn and runway against the stated minimum 12-month outlook, including financing activity after March 30, 2023.
- Check subsequent clinical and regulatory updates for LSTA1 and the status of potential partners for XOWNA, HONEDRA, and LSTA201.
- Assess the evidentiary limits of LSTA1’s early clinical results and the implications of LSTA201’s lack of a consistent kidney-function signal.
- Verify potential dilution from outstanding options, warrants, restricted stock units, and future financing; at year-end, the filing listed approximately 1.39 million options, 1.42 million warrants, and 48,000 restricted stock units.
- Monitor the Lingmed litigation, merger integration, NOL limitations, and Nasdaq continued-listing compliance.